Summary of Study ST000455

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000351. The data can be accessed directly via it's Project DOI: 10.21228/M8PC8X This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Download binned data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000455
Study TitleUtilizing Metabolomics to Understand Novel Anti-Desmoid Tumor Drugs (part II)
Study SummaryThis pilot study will use broad spectrum metabolomics to study the tumorigenesis process of fibroblasts to desmoids by investigating paired desmoid and fibroblast cell lines, in addition to unaffected fibroblast cells. Additionally, this pilot study will explore the effects of two of the active drugs identified on the desmoid and fibroblast cells.
RTI International
Last NameMercier
First NameKelly
Address3040 E. Cornwallis Road
Submit Date2016-08-31
Raw Data AvailableYes
Raw Data File Type(s)1r
Analysis Type DetailNMR
Release Date2017-12-06
Release Version1
Kelly Mercier Kelly Mercier application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000351
Project DOI:doi: 10.21228/M8PC8X
Project Title:Utilizing Metabolomics to Understand Novel Anti-Desmoid Tumor Drugs
Project Summary:Desmoid tumors (DT) are locally invasive soft tissue growths with no directed therapies currently. While two genes (β-catenin and adenomatous polyposis coli) have been found in patients who develop desmoids, it is unclear how these mutations and other downstream mechanisms lead to desmoid tumorigenesis. Extensive research has been explored in the molecular biology of desmoids; however, the use of metabolomics to understand the how the low molecular weight complements of cells, tissues, and biological fluids are perturbed by this highly localized disease. Additionally, the Desmoid Collaboration for a Cure has identified 45 active drugs against primary cell lines. It is unclear how these therapies perturb the metabolome, outside the Wnt and notch pathways.
Institute:RTI International
Last Name:Mercier
First Name:Kelly
Address:3040 E. Cornwallis Road


Subject ID:SU000476
Subject Type:Human Cell Media
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human


Subject type: Human Cell Media; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Treatment Growth_type
SA023061M_5Blank Blank
SA023062M_4Blank Blank
SA023063M_6Blank Blank
SA023064M_7Blank Blank
SA023065M_8Blank Blank
SA023066M_2Blank Blank
SA023067M_3Blank Blank
SA023068M_1Blank Blank
SA023079M_10Das. Normal
SA023080M_9Das. Normal
SA023081M_17Das. Normal
SA023082M_18Das. Normal
SA023083M_34Das. Tumor
SA023084M_33Das. Tumor
SA023085M_26Das. Tumor
SA023086M_25Das. Tumor
SA023087M_42Das. Unaffected
SA023088M_41Das. Unaffected
SA023069M_11DMSO Normal
SA023070M_12DMSO Normal
SA023071M_19DMSO Normal
SA023072M_20DMSO Normal
SA023073M_35DMSO Tumor
SA023074M_27DMSO Tumor
SA023075M_28DMSO Tumor
SA023076M_36DMSO Tumor
SA023077M_43DMSO Unaffected
SA023078M_44DMSO Unaffected
SA023089M_21FAK Inh. 14 Normal
SA023090M_22FAK Inh. 14 Normal
SA023091M_14FAK Inh. 14 Normal
SA023092M_13FAK Inh. 14 Normal
SA023093M_30FAK Inh. 14 Tumor
SA023094M_38FAK Inh. 14 Tumor
SA023095M_37FAK Inh. 14 Tumor
SA023096M_29FAK Inh. 14 Tumor
SA023097M_45FAK Inh. 14 Unaffected
SA023098M_46FAK Inh. 14 Unaffected
SA023099M_16H2O Normal
SA023100M_15H2O Normal
SA023101M_23H2O Normal
SA023102M_24H2O Normal
SA023103M_31H2O Tumor
SA023104M_32H2O Tumor
SA023105M_40H2O Tumor
SA023106M_39H2O Tumor
SA023107M_47H2O Unaffected
SA023108M_48H2O Unaffected
SA023109MP_2Total Pool Total Pool
SA023110MP_3Total Pool Total Pool
SA023111MP_1Total Pool Total Pool
Showing results 1 to 51 of 51


Collection ID:CO000470
Collection Summary:An aliquot of the media following treatment was collected, and the remainder of the media was aspirated.
Sample Type:Fibroblasts


Treatment ID:TR000490
Treatment Summary:Primary cell cultures of desmoid tumor samples were established as previously described [1,2]. Monolayer cell cultures were grown in DMEM supplemented with 5% fetal bovine serum and maintained at 37°C in 5% CO2. Cells were divided when confluent and experiments were performed between the third and sixth passages. Approximately 10 x 106 cells were treated with 1.0uM Dasatinib (Selleck, Houston, USA) dissolved in DMSO, or 0.5uM FAK Inhibitor 14 (Cayman Chemicals Company, Michigan, USA) dissolved in water. Cells were incubated in fresh media containing the inhibitors, or vehicle, for 24 hours.

Sample Preparation:

Sampleprep ID:SP000483
Sampleprep Summary:Cell media was extracted with 50% acetonitrile:water, vortexed, and centrifuged. An analytical quality control (QC) total pool was generated from equal aliquots from all of the media samples, divided into three total pool aliquots, and processed identically to the media study samples. All study and pool samples were lyophilized to dryness and reconstituted in a 0.2M phosphate buffer, pH 7.4, in D2O with 10% Chenomx ISTD and 6mM Imidazole.


Analysis ID:AN000712
Analysis Type:NMR
Num Factors:14


NMR ID:NM000079
Analysis ID:AN000712
Instrument Name:Bruker Avance III
Instrument Type:FT-NMR
NMR Experiment Type:1D 1H
Spectrometer Frequency:700 MHz